eClinical Tech News

Alumis has delivered positive Phase 3 topline results for envudeucitinib, its highly selective oral TYK2 inhibitor, in moderate-to-severe plaque...

electroCore posted record 2025 revenue of $32.0 million, up 27% year over year, and guided to approximately 30% growth...

Relmada Therapeutics reported 12-month phase 2 results for NDV-01 in non-muscle invasive bladder cancer showing a 95% complete response...

Alumis reported positive topline results from two Phase 3 trials of envudeucitinib in moderate-to-severe plaque psoriasis, with approximately 65%...

Gilead has exercised its option to license Assembly Biosciences’ helicase-primase inhibitor program for recurrent genital herpes, taking over ABI-5366...

SELLAS Life Sciences signaled a catalyst-heavy 2026 in acute myeloid leukemia. The company is approaching the final overall survival...

Humacyte has entered a registered direct offering to sell 25 million shares of common stock for expected gross proceeds...

Pelthos Therapeutics posted its first meaningful commercial snapshot as a pediatric dermatology-focused player, reporting $16.2 million in net product...

Longeveron outlined a pivotal year ahead, confirming it remains on track to deliver top-line data in the third quarter...

Trevi Therapeutics has secured end-of-Phase 2 alignment with FDA for Haduvio (oral nalbuphine ER) in idiopathic pulmonary fibrosis (IPF)-related...